Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma

Anticancer Res. 2010 Aug;30(8):3125-8.


We describe the case of a patient with terminal adenocarcinoma of the lung with no response to lymphokine-activated killer (LAK) cell therapy alone who distinctly responded clinically to a combination of high-dose glucocorticoids (GC) and LAK cell therapy, administered by chance. However, after decreasing the dose of GC because of gastrointestinal bleeding caused by the high-dose treatment, there was no response on restarting GC plus LAK cell therapy. The clinical course of this case strongly suggests that local inflammation in the vicinity of tumors should be adequately suppressed in patients with advanced cancer who receive immunotherapy.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Betamethasone / administration & dosage
  • Betamethasone / therapeutic use*
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Humans
  • Killer Cells, Lymphokine-Activated / immunology*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Treatment Outcome


  • Betamethasone